The efficacy of lenalidomide in the patient with plasma cell myeloma coexisting with myelodysplatic syndrome associated with isolated del 5q–

Abstract

Treatment-related extension of survival has recently been observed in patients with plasma cell myeloma (PCM). However, chemotherapy also increases he incidence of other cancers for this patient group; myelodysplastic syndrome (MDS) being a classic example. A rare case-study is presented of a patient diagnosed with PCM coexisting with MDS associated with isolated del 5q– (MDS 5q–). After lenalidomide treatment, partial remission from PCM was observed, also accompanied by, partial cytogenic remission of MDS 5q–.